EGFR and non-small cell lung carcinoma: Of the 227 patients (84 males, 143 females; mean age, 60.8 ± 8.1 years), 96 patients had stage IA and IB NSCLC, 55 patients received 3-4 cycles of chemotherapy (TP regimen, n=32; NP regimen, n=23) prior to adjuvant EGFR-TKI therapy.